Xenetic Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.2M
- Price
- $3.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.90%
- Volume
- 84.3K
About
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Quick stats
Shares outstanding2.3M
Computed float1.9M
Float / shares83.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534525
Websitehttps://www.xeneticbio.com
AI Summary
AI-generated1/6
minorneutralearnings
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Xenetic reported Q2 2026 royalty revenue of $0.7 million, up 12% year-over-year, while cash reserves decreased to $6.5 million from $7.9 million at year-end 2025.
The company highlighted positive translational data for its DNase platform presented at ASCO and noted that partner PeriNess received approval for an investigator-initiated study in Israel.
G&A expenses rose 64% to $1.1 million due to legal costs associated with a strategic review process, contributing to a net loss of $0.9 million for the quarter.
Red flags
- Cash balance decreased by approximately $1.4 million (or 18%) over six months to $6.5 million
- G&A expenses increased 64% primarily due to legal costs associated with strategic review
- Net loss widened to $0.9 million from $0.7 million in the prior year period